Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses

12 Months Ended

Dec. 31, 2017

Accrued expenses and other current liabilities consisted of the following (in thousands):



	Years Ended December 31,
	2017		2016
Compensation expense	$	2,325	$	1,198
Professional fees	1,322		624
Research and development fees	791		1,284
Audit and tax fees	424		455
Other current liabilities	1,308		158
Total	$	6,170	$	3,719